International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 747-754 , 1 March 2010

Dose–Volume Constraints to Reduce Rectal Side Effects From Prostate Radiotherapy: Evidence From MRC RT01 Trial ISRCTN 47772397

  • Sarah L. Gulliford, Ph.D.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • Corresponding Author InformationReprint requests to: Sarah L. Gulliford, Ph.D., Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Cotswold Rd., Sutton SM2 5NG United Kingdom. Tel: (+44) 208-661-3675; Fax: (+44) 208-643-3812
    • ,
  • Kerwyn Foo, F.R.A.N.Z.C.R.

      Affiliations

    • Department of Radiation Oncology, Illawarra Cancer Care Centre, Wollongong Hospital, NSW, Australia
    • ,
  • Rachel C. Morgan, M.Sc.

      Affiliations

    • Cancer Group, Medical Research Council Clinical Trials Unit, London, United Kingdom
    • ,
  • Edwin G. Aird, Ph.D.

      Affiliations

    • Department of Medical Physics, Mount Vernon Hospital, Northwood, United Kingdom
    • ,
  • A. Margaret Bidmead, M.Sc.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • ,
  • Helen Critchley, Ph.D.

      Affiliations

    • Atomic Weapons Establishment, Aldermaston, United Kingdom
    • ,
  • Philip M. Evans, D.Phil.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • ,
  • Stefano Gianolini, Ph.D.

      Affiliations

    • Tomotherapy Inc., Culliganlaan, Diegem, Belgium
    • ,
  • W. Philip Mayles, Ph.D.

      Affiliations

    • Department of Physics, Clatterbridge Centre for Oncology, Wirral, United Kingdom
    • ,
  • A. Rollo Moore, M.Sc.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • ,
  • Beatriz Sánchez-Nieto, Ph.D.

      Affiliations

    • Servicio de Radioterapia, Clinica Alemana de Santiago, Santiago, Chile
    • ,
  • Mike Partridge, Ph.D.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • ,
  • Matthew R. Sydes, C.Stat

      Affiliations

    • Cancer Group, Medical Research Council Clinical Trials Unit, London, United Kingdom
    • ,
  • Steve Webb, D.Sc.

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    • ,
  • David P. Dearnaley, F.R.C.R.

      Affiliations

    • Department of Academic Urology, Institute of Cancer Research and Royal Marsden Hospitals, Sutton, United Kingdom

Received 15 October 2008 ,Revised 11 February 2009 ,Accepted 11 February 2009.

References 

  1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  2. Al Mamgani A, Heemsbergen WD, Peeters ST, et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;73:685–691
  3. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  4. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  5. Boersma LJ, van den BM, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer, using dose–volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  6. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). Int J Radiat Oncol Biol Phys. 2003;55:688–694
  7. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64:1–12
  8. Koper PC, Heemsbergen WD, Hoogeman MS, et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1072–1082
  9. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151–1161
  10. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer: II. Volume effects and dose–volume histograms. Int J Radiat Oncol Biol Phys. 2001;49:685–698
  11. Sydes MR, Stephens RJ, Moore AR, et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): Methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004;72:199–211
  12. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007;83:31–41
  13. Greco C, Mazzetta C, Cattani F, et al. Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol. 2003;69:215–222
  14. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose–volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  15. Wachter S, Gerstner N, Goldner G, et al. Rectal sequelae after conformal radiotherapy of prostate cancer: Dose–volume histograms as predictive factors. Radiother Oncol. 2001;59:65–70
  16. Akimoto T, Muramatsu H, Takahashi M, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;60:1033–1039
  17. Tucker SL, Cheung R, Dong L, et al. Dose–volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:353–365
  18. Denham JW, O'Brien PC, Dunstan RH, et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol. 1999;51:43–53
  19. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: A new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8:1007–1017
  20. Skala M, Rosewall T, Dawson L, et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:690–698
  21. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130–1137
  22. Vargas C, Martinez A, Kestin LL, et al. Dose–volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1297–1308
  23. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  24. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: Dose–volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:1314–1321
  25. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  26. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: Ingredients for testing hypofractionation in prostate cancer—The CHHiP trial. Clin Oncol (R Coll Radiol). 2008;20:12–14
  27. Mangar SA, Sydes MR, Tucker HL, et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006;80:355–362
  28. Pilepich MV, Krall JM, Sause WT, et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate—Analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys. 1987;13:351–357
  29. LENT-SOMA tables. Radiother Oncol. 1995;35:17–60
  30. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012
  31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  32. Bauman G, Rodrigues G. In regard to Fiorino et al.: Rectal dose–volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953–962). Int J Radiat Oncol Biol Phys. 2004;59:912–914
  33. Elliott R, Burnet N, Dunning A, et al. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol). 2008;19:S15

 Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

 Supported and coordinated by the U.K. Medical Research Council, Institute of Cancer Research, and Cancer Research U.K. Section of Radiotherapy Grant C46/A2131.

 Conflict of interest: M. Sydes and R. Morgan are employed by the trial sponsor (Medical Research Council United Kingdom).

PII: S0360-3016(09)00254-5

doi: 10.1016/j.ijrobp.2009.02.025

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 747-754 , 1 March 2010

Article Tools

* Image Usage & Resolution